Brookline Capital Management Weighs in on CATX Q1 Earnings

Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Analysts at Brookline Capital Management reduced their Q1 2025 earnings per share estimates for Perspective Therapeutics in a report released on Wednesday, March 26th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($0.30) per share for the quarter, down from their prior estimate of ($0.29). Brookline Capital Management has a "Strong-Buy" rating on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Perspective Therapeutics' FY2025 earnings at ($1.43) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($2.07) EPS.

Other research analysts have also issued reports about the company. Royal Bank of Canada lowered their price target on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research report on Thursday, March 27th. Scotiabank started coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price objective on the stock. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Tuesday, March 4th. Wedbush reissued an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Perspective Therapeutics in a report on Monday. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of "Buy" and an average price target of $14.44.

Perspective Therapeutics Stock Down 4.4 %

CATX traded down $0.09 on Monday, hitting $1.96. The company had a trading volume of 1,182,906 shares, compared to its average volume of 1,007,418. The company's fifty day moving average price is $2.82 and its 200 day moving average price is $6.04. Perspective Therapeutics has a 1 year low of $1.90 and a 1 year high of $19.05.

Institutional Trading of Perspective Therapeutics

Hedge funds have recently modified their holdings of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Perspective Therapeutics by 19.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company's stock valued at $224,000 after purchasing an additional 11,472 shares during the last quarter. Velan Capital Investment Management LP bought a new stake in shares of Perspective Therapeutics in the 4th quarter valued at $1,595,000. Squarepoint Ops LLC bought a new stake in shares of Perspective Therapeutics in the 4th quarter valued at $626,000. Wexford Capital LP acquired a new stake in Perspective Therapeutics during the 4th quarter worth $64,000. Finally, Two Sigma Advisers LP bought a new position in Perspective Therapeutics during the fourth quarter worth about $484,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Insider Activity

In related news, Director Robert F. Williamson III purchased 22,192 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The stock was purchased at an average cost of $2.27 per share, with a total value of $50,375.84. Following the acquisition, the director now directly owns 70,837 shares in the company, valued at approximately $160,799.99. This trade represents a 45.62 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Juan Graham acquired 33,333 shares of the firm's stock in a transaction dated Friday, March 28th. The shares were purchased at an average cost of $2.25 per share, for a total transaction of $74,999.25. Following the acquisition, the chief financial officer now directly owns 35,354 shares in the company, valued at $79,546.50. This represents a 1,649.33 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 115,696 shares of company stock worth $256,344 over the last 90 days. 3.52% of the stock is owned by company insiders.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.